Global Footprint Dual European and US presence through Invectys SAS Paris and Invectys USA Houston enables cross border R&D, regulatory alignment, and access to European and American trial networks, creating opportunities for partnerships with CROs, CMOs, and clinical operators to accelerate trials.

HLA-G Advantage The company pursues first-in-class HLA-G targeted CAR T therapies for solid tumors, offering unique collaboration opportunities in translational research, biomarker development, manufacturing partnerships, and licensing of a differentiated immunotherapy platform.

Strategic Collaborations Awards recognizing translational development and a strategic collaboration with MD Anderson CTMC underscore Invectys' capability to deliver translational research and scalable cell therapy manufacturing, presenting channels for co development and process optimization partnerships.

Clinical Momentum Active participation in major conferences such as ASCO 2025 with first in human trial design announcements signals a mature clinical program and openness to partner with trial operators, early phase CROs, and regulatory experts to de risk and accelerate development.

Funding Outlook Private funding milestones and investor interest indicate appetite for milestone driven partnerships, co development or licensing to advance HLA-G therapies, complementing the company’s private status and clinical focus.